In 2014, olaparib was the first PARP inhibitor to be approved by the FDA for advanced BRCA-mutated ovarian cancer, followed by rucaparib which was licensed for the same indication in 2016 (https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications)16,17. Here, PARP1 is linked to cancer.